Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial"

Affiliations

¹ KfH Kidney Center, Munich (J.F.E.M.).
² Department of Nephrology, Friedrich Alexander University of Erlangen, Germany (J.F.E.M.).
³ Tulane University Health Sciences Center, School of Medicine, New Orleans, LA (V.F.).
⁴ Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel (O.M., I.R.).
⁵ Novo Nordisk A/S, Søborg, Denmark (B.G., T.I., B.J.v.S).
⁶ Imperial College London, UK (N.R.P.).

Comment

Johannes F E Mann et al. Circulation. 2019.

. 2019 May 28;139(22):e1017-e1018.

doi: 10.1161/CIRCULATIONAHA.119.040419. Epub 2019 May 28.

¹ KfH Kidney Center, Munich (J.F.E.M.).
² Department of Nephrology, Friedrich Alexander University of Erlangen, Germany (J.F.E.M.).
³ Tulane University Health Sciences Center, School of Medicine, New Orleans, LA (V.F.).
⁴ Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel (O.M., I.R.).
⁵ Novo Nordisk A/S, Søborg, Denmark (B.G., T.I., B.J.v.S).
⁶ Imperial College London, UK (N.R.P.).

No abstract available

Comment on

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Mann JFE, et al. Circulation. 2018 Dec 18;138(25):2908-2918. doi: 10.1161/CIRCULATIONAHA.118.036418. Circulation. 2018. PMID: 30566006 Free PMC article. Clinical Trial.
Letter by Xie et al Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
Xie J, Jiang M, Li L. Xie J, et al. Circulation. 2019 May 28;139(22):e1015-e1016. doi: 10.1161/CIRCULATIONAHA.118.039071. Epub 2019 May 28. Circulation. 2019. PMID: 31136224 No abstract available.